Head to Head Survey: Agilon Health (NYSE:AGL) and Fulgent Genetics (NASDAQ:FLGT)Defense World · Oct 18, 2026
Fulgent to Announce Third Quarter 2026 Financial Results on Thursday, November 5, 2026Business Wire · Oct 15, 2026
Corient Private Wealth LP Lowers Stake in Fulgent Genetics, Inc. $FLGTDefense World · Sep 28, 2026
PRPO vs. FLGT: Which Cancer Diagnostics Stock Has More Upside Now?Zacks Investment Research · Sep 22, 2026
Hsbc Holdings PLC Purchases New Position in Fulgent Genetics, Inc. $FLGTDefense World · Sep 2, 2026
Fulgent Genetics, Inc. (FLGT) Q2 2026 Earnings Call TranscriptSeeking Alpha · Jul 31, 2026Fulgent Genetics, Inc., together with its affiliated companies, offers a comprehensive suite of COVID-19, molecular diagnostic, and genetic testing services to healthcare providers and individuals globally. Their diverse array of genetic tests covers a wide range of applications, including extensive oncology panels and solid tumor molecular profiling for cancer identification, Beacon carrier screening for inherited conditions, and specialized rapid whole genome testing for critically ill infants in NICU and PICU units. Other offerings include a newborn genetic analysis panel, a front-line test to sequence ataxia-related variants, and patient-initiated genetic testing via Picture Genetics.
| Date | Est. | Actual | |
|---|---|---|---|
| Jul 30, 2026 | -$0.46 | -$0.58 | Miss |
| May 1, 2026 | -$0.35 | -$0.36 | Miss |
| Feb 27, 2026 | $0.03 | $0.16 | Beat |
| Nov 7, 2025 | -$0.24 | $0.14 | Beat |
| Aug 1, 2025 | -$0.23 | $0.07 | Beat |
| May 2, 2025 | -$0.19 | $0.04 | Beat |